Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on September 29, 2016. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel and governance events rather than financial performance.
Material Changes
- Board Appointment: On September 29, 2016, the Board appointed Matthew Sherman, M.D., as a Class II director. His term expires at the next annual meeting of stockholders or upon earlier death, resignation, or removal.
- Board Departure: The filing references the prior resignation of Kurt C. Graves, which became effective on June 14, 2016.
- Compensatory Arrangement: Dr. Sherman was granted a stock option to purchase 8,800 shares of common stock. The exercise price equals the fair market value on the grant date. The option has a ten-year term with a vesting schedule of 25% on the first anniversary and the remainder vesting monthly over the subsequent 36 months.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or specific risk factors. Management commentary is limited to the professional background of Dr. Sherman, highlighting his experience as Chief Medical Officer at Acceleron Pharma, Inc., and his prior roles at Synta Pharmaceuticals, Genetics Institute, and Wyeth Pharmaceuticals. The appointment is intended to bring medical and clinical development expertise to the Board.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following the appointment of Dr. Sherman.
- Review the terms of the stock option grant (8,800 shares) and its impact on potential dilution.
- Confirm the status of the company's clinical development pipeline, given the new director's background in oncology and hematology.
- Check for any subsequent filings regarding the resignation of Kurt C. Graves or other board changes.